Straumann Group is set to inject between 60 and 80 million CHF into its Villeret facility over the next five years, reinforcing its role as a key hub for innovation and precision manufacturing within the company’s global network.
Strategic Investment and Production Realignment
The substantial investment aims to enhance advanced technologies, modernize infrastructure, and cultivate future-ready skills among Villeret’s workforce. Concurrently, Straumann plans to progressively transfer the production of products destined for the Chinese market to its newly licensed Shanghai campus. This move is designed to bolster competitiveness in the local Chinese market, which currently accounts for over 15% of the group’s global revenue.
Workforce Adjustments and Market Adaptation
Over the past seven years, Villeret has seen its employee base double from approximately 550 to over 1,000, driven by escalating global demand and the implementation of the Volume-Based Procurement (VBP) system in China in January 2023. To align with the shifting production needs, up to 250 positions in Villeret may be affected as the workforce adjusts to pre-VBP levels. A 14-day consultation process is underway to engage with employees and explore socially responsible solutions.
The introduction of the VBP-2.0 cycle in China, scheduled for January 2026, underscores the importance of local manufacturing in securing market access and participating in public tenders. By relocating production to Shanghai, Straumann not only ensures continued growth in a critical region but also strengthens its manufacturing presence in Switzerland.
The planned investments will open new avenues for Villeret, particularly through the production of high-value products like the newly launched iEXCEL high-performance implant system, which plays a central role in Straumann’s global growth strategy.
Straumann Group, headquartered in Basel, Switzerland, employs around 12,000 people worldwide and operates in more than 100 countries. The company focuses on dental solutions, including implants, instruments, CAD/CAM prosthetics, orthodontic appliances, biomaterials, and digital dental technologies.
Inferences:
- Straumann’s investment signals a long-term commitment to the Villeret site despite shifting some production to Shanghai.
- The relocation to Shanghai is a strategic response to China’s VBP system, aiming to maintain market access and competitiveness.
- Workforce reductions in Villeret may impact local employment, though the company seeks to manage this transition responsibly.
- Focus on high-value products like iEXCEL indicates a strategy to prioritize quality and innovation in key markets.
Straumann’s dual approach of investing in Villeret while enhancing its Shanghai operations demonstrates a balanced strategy to sustain growth and adapt to evolving market dynamics. By prioritizing high-value manufacturing and local production capabilities, Straumann is positioning itself to meet the demands of the Chinese market effectively while maintaining its strong foothold in Switzerland. This strategic realignment not only supports the company’s global expansion goals but also ensures resilience against market fluctuations and regulatory changes in key regions.
This article has been prepared with the assistance of AI and reviewed by an editor. For more details, please refer to our Terms and Conditions. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author.
